N-(4-(3,5-DICHLORO-4-(1,1,2,2-TETRAFLUOROETHOXY)PHENOXY)PHENYLCARBAMOYL)-2,6-DIFLUOROBENZAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KVWCBAXIVDASII-UHFFFAOYSA-N
Smiles	FC(F)C(F)(F)Oc1c(Cl)cc(Oc2ccc(NC(=O)NC(=O)c3c(F)cccc3F)cc2)cc1Cl
InChI	InChI=1S/C22H12Cl2F6N2O4/c23-13-8-12(9-14(24)18(13)36-22(29,30)20(27)28)35-11-6-4-10(5-7-11)31-21(34)32-19(33)17-15(25)2-1-3-16(17)26/h1-9,20H,(H2,31,32,33,34)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H12Cl2F6N2O4
Molecular Weight	553.24
AlogP	7.18
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	7.0
Polar Surface Area	76.66
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	36.0

Assay Description	Organism	Bioactivity
Insecticidal activity against fourth-instar larval stage of Culex pipiens pallens (mosquito) assessed as mortality at 0.0025 mg/l at 25 +/-1 degC after 8 days	Culex pipiens pallens	50.0 %
Insecticidal activity against fourth-instar larval stage of Culex pipiens pallens (mosquito) assessed as mortality at 0.005 mg/l at 25 +/-1 degC after 8 days	Culex pipiens pallens	100.0 %
Insecticidal activity against fourth-instar larval stage of Mythimna separata (Oriental armyworm) infested drug-pretreated corn leaves assessed as mortality at 1 mg/l at 25 +/-1 degC after 4 days	Mythimna separata	0.0 %
Insecticidal activity against fourth-instar larval stage of Mythimna separata (Oriental armyworm) infested drug-pretreated corn leaves assessed as mortality at 2.5 mg/l at 25 +/-1 degC after 4 days	Mythimna separata	100.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2227782
PubChem	52920641

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).